A Phase 1b Study of SAR65098 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

ID Number 16-0568

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to test the safety of SAR650984 with carfilzomib at different dose levels.  We want to find out what effects, good and/or bad, the combination has on you and your myeloma.  SAR650984 is an antibody directed against CD38, a receptor antigen.  SAR650984 may stop the growth of some blood cancers  SAR650984 is an investigational drug, which means it has not been approved for use by the U.S. Food and Drug Administration (FDA).

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: Yes